Author

M Kavanagh-Williamson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. D. Davidson· 1 shared A. Kerelsky· 1 shared A. P. Possemato· 1 shared A. T. Harding· 1 shared A. Tata· 1 shared B. E. Heaton· 1 shared B. E. Nilsson-Payant· 1 shared B. M. Cohen· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. D. Davidson

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

T. M. Yaron, B. E. Heaton, T. M. Levy, J. L. Johnson, T. X. Jordan, B. M. Cohen, A. Kerelsky, T.-Y. Lin, K. M. Liberatore, D. K. Bulaon, E. R. Kastenhuber, M. N. Mercadante, K. Shobana-Ganesh, L. He, R. E. Schwartz, , M Kavanagh-Williamson

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

bioRxiv · Aug 14, 2020 · PreprintMicrobiology